TG-5

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameTG-5
Drug Alias NameSARS CoV 3CL protease inhibitor (TaiGen)SARS therapy (TaiGen)TG-5
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSARS-CoV-2-3C-like-proteinase inhibitors
TargetsSARS-CoV-2-3C-like-proteinase
Therapy Area/IndicationsSevere Acute Respiratory Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTaiGen Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTaiGen Biotechnology Co Ltd
Active IndicationsN/A
Inactive IndicationsSevere Acute Respiratory Syndrome

Other Information

ATC CodeN/A
Related LinksN/A